| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/24/2002 | US20020010153 Oral delivery of macromolecules |
| 01/24/2002 | US20020010150 Homostatic compositions of polyacids and polyalkylene oxides and methods for their use |
| 01/24/2002 | US20020010146 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 01/24/2002 | US20020010142 Parasiticidal formulation and a method of making this formulation |
| 01/24/2002 | US20020010131 Reductive alkylation process |
| 01/24/2002 | US20020010130 Adding purified fibronectin to basic water; wound healing gels |
| 01/24/2002 | US20020010128 Treating atopic dermatitis and/or skin photodamage, by administering a HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase) inhibitor |
| 01/24/2002 | US20020009798 Ob protein compositions and methods |
| 01/24/2002 | US20020009789 Powder containing physiologically active peptide |
| 01/24/2002 | US20020009522 Coating material and coated powder |
| 01/24/2002 | US20020009503 Antiallergic composition and antipruritic composition |
| 01/24/2002 | US20020009502 Water, sodium chloride, potassium chloride, sodium citrate, potassium citrate, carbohydrates and structuring agents; masks unpleasant tastes |
| 01/24/2002 | US20020009500 Therapeutic platelets and methods |
| 01/24/2002 | US20020009496 Spraying a suspension of microionized fenofibrate and polyvinylpyrrolidone onto an inert hydrosoluble carrier; immediate-release; improved dissolution |
| 01/24/2002 | US20020009494 Spray drying |
| 01/24/2002 | US20020009493 Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
| 01/24/2002 | US20020009492 Crosslinked polymer |
| 01/24/2002 | US20020009491 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/24/2002 | US20020009489 Atopic dermatitis treatment method |
| 01/24/2002 | US20020009487 Mixture containing amine |
| 01/24/2002 | US20020009478 Aqueous liquid containing colloidal particles |
| 01/24/2002 | US20020009463 Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces |
| 01/24/2002 | US20020009456 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| 01/24/2002 | US20020009454 Composition and method for treating inflammatory diseases |
| 01/24/2002 | US20020009441 Administering mixture of binding agent and active materials |
| 01/24/2002 | US20020009433 Method of increasing the bioavailability and tissue penetration of azithromycin |
| 01/24/2002 | US20020009431 Method for transplanting cells into the brain and therapeutic uses therefor |
| 01/24/2002 | US20020009426 Drug delivery |
| 01/24/2002 | US20020009416 Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system |
| 01/24/2002 | DE10053375C1 Transdermal therapeutic system with light-sensitive agent in polymer matrix and backing, useful for therapy with e.g. nicotine, nifedipine, lacidipine, gestagen, vitamin B 12 or antibiotic, contains colorless ultraviolet absorber |
| 01/24/2002 | DE10045374A1 Sustained release microparticles and their preparation using a multi-emulsion process, for delivery of drugs for up to 6 months or longer |
| 01/24/2002 | CA2416698A1 Hydrogel films and methods of making and using therefor |
| 01/24/2002 | CA2416487A1 Stimulation of bone growth with thrombin peptide derivatives |
| 01/24/2002 | CA2416004A1 Method for encapsulating fine solid particles in the form of microcapsules |
| 01/24/2002 | CA2415922A1 Pharmaceutical compositions containing dds compound |
| 01/24/2002 | CA2415712A1 Protein complex serving as a vehicle for orally administerable medicaments |
| 01/24/2002 | CA2415285A1 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds |
| 01/24/2002 | CA2415128A1 An implantable or insertable therapeutic agent delivery device |
| 01/24/2002 | CA2414780A1 Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
| 01/24/2002 | CA2382085A1 Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides |
| 01/23/2002 | EP1174416A1 Conjugated fatty acid esters |
| 01/23/2002 | EP1174152A1 Opioid peptide inclusion complex |
| 01/23/2002 | EP1174148A1 Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same |
| 01/23/2002 | EP1174139A2 Use of mometasone furoate for treating airway passage and lung diseases |
| 01/23/2002 | EP1174138A2 Use of mometasone furoate for treating airway passage and lung diseases |
| 01/23/2002 | EP1174137A1 Patches containing buprenorphine hydrochloride |
| 01/23/2002 | EP1174136A2 Oral pharmaceutical dosage form containing a proton pump inhibitor |
| 01/23/2002 | EP1174133A1 Pharmaceutical compositions containing amorphous mupirocin |
| 01/23/2002 | EP1174132A1 Percutaneous absorption preparations containing oxybutynin |
| 01/23/2002 | EP1174126A1 Antibody and polyalkylene glycol-bonded liposome |
| 01/23/2002 | EP1174124A1 Percutaneous administration preparations |
| 01/23/2002 | EP1174110A1 Cosmetic or pharmaceutical solid composition comprising bis-acyl-amides |
| 01/23/2002 | EP1174109A2 Combinations of active substances respectively adducts from cyclodextrins and at least a quinone and/or at least a hydroquinone and use of such combinations of active substances in cosmetic preparations |
| 01/23/2002 | EP1173766A1 A tenascin-c isoform as a marker for neoplasias |
| 01/23/2002 | EP1173765A1 Diagnostic and therapeutic use of antibodies against the urokinase receptor |
| 01/23/2002 | EP1173600A2 Cationic peg-lipids and methods of use |
| 01/23/2002 | EP1173590A2 Zymogen activation system |
| 01/23/2002 | EP1173551A2 Pseudotyped retroviral vector for gene therapy of cancer |
| 01/23/2002 | EP1173521A1 Stable, aqueous dispersions and stable, water-dispersible dry powders of xanthophylls, and production and use of the same |
| 01/23/2002 | EP1173517A1 In situ forming hydrogels |
| 01/23/2002 | EP1173482A1 Insulin crystals for pulmonary administration |
| 01/23/2002 | EP1173481A1 Inactivated cytokines for immunisation |
| 01/23/2002 | EP1173475A1 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients |
| 01/23/2002 | EP1173474A1 Membrane disruptive peptides covalently oligomerized |
| 01/23/2002 | EP1173453A1 Crystallization of glucopyranosylalditols, crystalline glucopyranosylalditol product and use thereof |
| 01/23/2002 | EP1173245A2 Compositions for aerosolization and inhalation |
| 01/23/2002 | EP1173224A1 Polyethyleneimine:dna formulations for aerosol delivery |
| 01/23/2002 | EP1173223A2 Conjugates as therapies for cancers and prostate diseases |
| 01/23/2002 | EP1173222A2 Conjugate having a cleavable linkage for use in a liposome |
| 01/23/2002 | EP1173221A2 Releasable linkage and compositions containing same |
| 01/23/2002 | EP1173220A2 Targeting of infectious agents bearing host cell proteins |
| 01/23/2002 | EP1173218A1 Compositions for treatment of disorders of the oesophagus |
| 01/23/2002 | EP1173217A2 Enhanced delivery of nucleic acid-based drugs |
| 01/23/2002 | EP1173216A1 Pharmaceutical formulations |
| 01/23/2002 | EP1173215A1 Over-coated chewing gum formulations |
| 01/23/2002 | EP1173205A1 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
| 01/23/2002 | EP1173197A2 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue |
| 01/23/2002 | EP1173192A2 Methods and compositions for targeted drug delivery |
| 01/23/2002 | EP1173189A1 Asialocytokines and treatment of liver disease |
| 01/23/2002 | EP1173178A1 Apomorphine and sildenafil composition |
| 01/23/2002 | EP1173173A1 Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives |
| 01/23/2002 | EP1173171A1 Novel anticoagulant injectable composition |
| 01/23/2002 | EP1173157A2 Treatment of trauma |
| 01/23/2002 | EP1173155A1 Gum pad for delivery of medication to mucosal tissues |
| 01/23/2002 | EP1173154A1 Chewing gum with dental benefits including calcium in a food grade acid |
| 01/23/2002 | EP1173153A1 Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants |
| 01/23/2002 | EP1173152A2 Solid pharmaceutical formulations of acid-sensitive proton-pump blockers |
| 01/23/2002 | EP1173151A1 Dry, mouldable drug formulation |
| 01/23/2002 | EP1173150A1 Cosmetic and/or pharmaceutical preparations |
| 01/23/2002 | EP1173149A1 Cosmetic and/or dietetic composition comprising a mixture of lycopene and olive leaf extract |
| 01/23/2002 | EP1173147A2 Sunscreen agents containing hydroxycarboxylic acid alkyl,-and/or alkenyloligo- glycoside esters |
| 01/23/2002 | EP1173138A1 Cosmetic or pharmaceutical utilisation of nanoscalic metal soaps |
| 01/23/2002 | EP1094802B1 Pharmaceutical composition for injection based on paracetamol |
| 01/23/2002 | EP1056856B1 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 01/23/2002 | EP1043979B1 Compositions for the transdermal and dermal administration of biologically active agents |
| 01/23/2002 | EP1023055B1 Inhibition of crystallization in transdermal devices |
| 01/23/2002 | EP0888545B1 Super-paramagnetic particles with increased r 1 relaxivity, processes for producing said particles and use thereof |
| 01/23/2002 | EP0840621B1 Hormone patch |
| 01/23/2002 | EP0726771B1 Desferrioxamine oral delivery system |
| 01/23/2002 | EP0658118B1 Vaccines against group c neisseria meningitidis |